Otsuka Acquires Cantargia’s CAN10 IL1RAP Antibody Immunology Program
Cantargia AB has announced a landmark agreement with Japanese pharma giant Otsuka Pharmaceutical Co., Ltd., granting Otsuka exclusive global rights
Read moreCantargia AB has announced a landmark agreement with Japanese pharma giant Otsuka Pharmaceutical Co., Ltd., granting Otsuka exclusive global rights
Read moreHarbour BioMed has entered into a global strategic collaboration with Otsuka Pharmaceutical Co., Ltd., granting Otsuka exclusive rights to develop,
Read moreImmunoglobulin (Ig), a multifaceted protein, stands as a sentinel against foreign invaders in the body, thanks to its fragment antigen-binding
Read morePfizer announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS® (brentuximab vedotin) in combination with
Read moreWuXi Biologics, a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), announced today, a new partnership with Candid Therapeutics,
Read moreSignatope offers custom assay and antibody development services under the SignaXIMTM trademark, catering to the specific needs of pharmaceutical and
Read moreBehring Campus Eystrup (BCE) is a highly experienced CRO providing comprehensive and flexible custom antibody development services to the pharma
Read moreMerck KGaA (Merck) announced an investment today of more than €300 Million ($320.8m) in a new Life Science Research Centre
Read moreSwiss pharma giant Roche has entered an agreement to purchase Telavant Holdings, a Roivant company, owned by Roivant Sciences Ltd.
Read moreStressMarq manufactures and offers a wide range of products specifically developed to accelerate Parkinson’s disease research. StressMarq’s cutting-edge product range
Read more